# OnCo record nct04802759 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct04802759/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct04802759", "NCT04802759" ;
  schema:name "A Study Evaluating the Efficacy and Safety of Multiple Treatment Combinations in Participants With Breast Cancer"@en ;
  schema:description "A phase 1/2 trial of Giredestrant, Abemaciclib, Ipatasertib, Inavolisib, Ribociclib and Everolimus in HR-positive / HER2-negative breast cancer, run by Hoffmann-La Roche, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct04802759/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT04802759> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2021-06-22" ;
  onco:cancers <https://onco.cc/cancers/breast-hr-positive/> ;
  onco:drugs <https://onco.cc/drugs/giredestrant/>, <https://onco.cc/drugs/abemaciclib/>, <https://onco.cc/drugs/ipatasertib/>, <https://onco.cc/drugs/inavolisib/>, <https://onco.cc/drugs/ribociclib/>, <https://onco.cc/drugs/everolimus/>, <https://onco.cc/drugs/samuraciclib/> ;
  onco:companies <https://onco.cc/companies/flatiron-health/> .